Web de solicitud de admisión a los estudios de doctorado - Documentos a presentar. Cerrar o Enviar la Solicitud de Admisión. Dudas que se pueden plantear. Consultar resolución provisional. Presentar reclamación a la resolución provisional. Lista definitiva de admitidos. Realizar matrícula de doctorado. Solicitudes, impresos y certificados. Admisión condicionada a los estudios de doctorado. Presencialidad en los estudios de doctorado. Lea detenidamente este documento. Doctorado Subir.

Programa de Doctorado en Biología Fundamental y de Sistemas. Becas y Ayudas. Los titulados universitarios que, previa obtención de plaza en formación sanitaria especializada, hayan superado con evaluación positiva al menos dos años de formación en el programa de la especialidad en Ciencias de la Salud. Licenciados, Arquitectos o Ingenieros que estuvieran en posesión del Diploma de Estudios Avanzados obtenido de acuerdo con lo dispuesto en el R. Web para consultar el nivel meces de un título de grado: Web de ejemplo , en la que se ha consultado un Grado en Farmacia que tiene reconocido el nivel Meces tres por la Universidad de Granada: Nivel Meces del Grado en Farmacia.

La relación de programas que en el curso actual se ofertan puede hacerlo en el siguiente enlace: Líneas de Investigación Estructura del Programa: Algunos de los programas de doctorado indican en su web. Requisitos de Admisión Acceso y admisión - Baremación. Como se indicaba anteriormente, aparte de los requisitos de acceso cada programa de doctorado puede establecer determinados criterios de admisión.

Programa de Doctorado. La fecha de nacimiento es muy importante consignarla de forma correcta, sobre todo si el solicitante tiene expediente abierto en enseñanzas oficiales de la Universidad de Granada. No se ha recibido el correo electrónico con el enlace web: Puede ser que el correo electrónico indicado en el formulario anterior no se hiciera correctamente.

El formulario nos indica: Analizaremos primero la parte de documentos que se tienen que aportar: Web en español: Modelo de Solicitud. Se debe aportar una copia del título de Licenciatura, Ingeniería, Arquitectura, Grado o título equivalente. La beca Erasmus se divide a su vez en dos partes. Debes cumplir los mismos requisitos que se deben cumplir todos los años: Puedes consultar todos requisitos en detalle aquí:. Deberías informarte sobre ello en la web de tu universidad de destino.

Sí, siempre que no solapen las fechas de ambos programas de movilidad. No, los estudiantes de intercambio no pueden solicitar el programa Erasmus ni el Plan Propio. No debes preocuparte por ello. Toda la información actualizada al respecto puede encontrarse en:. Projects 1. Toward the harmonization of the pharmaceuticals liability systems. Research Items Illegal medicines as threats to public health. Full-text available. Apr The trade in illegal pharmaceuticals is a global problem for public health.

The transgressions of the rules that govern the distribution and marketing of medicinal products comes in many different forms, including substandard medicines, falsified drugs, counterfeits, ineffective medicines, falsely-labelled medicines and unregistered medicines. All of which breach different provisions of the pharmaceutical legislation and could be appropriately qualified as illegal. In order to prevent the presence in the market of illegal products is necessary a global approach to define the scope of the problem and the measures to be put in place. It corresponds to the administrative, civil and criminal law to define the different problems and establish the corresponding penalties.

Governments on their part should strengthen their controls to detect illegal medicines. The protection of intellectual property rights is interlinked with the protection from illegal medicines trade and a fundamental issue for the pharmaceutical sector and the patients. If we want better medicines, the patent system is the way to encourage it. An effective intellectual property system provide fair and efficient incentives for innovation.

Preguntas Frecuentes

The challenge for governments is to improve the chain of responsibilities to protect the pharmaceuticals market. The improvement of the enforcement of the administrative, civil and penal regulations is imperative. All rights reserved. The globalization of medicines as a challenge for governments. Oct Health is a global concern. The need for a globalized response is evident in the pharmaceutical industry.

Although pharmaceutical products are developed and marketed internationally, they are currently regulated only at national level. The pharmaceutical agencies regulate medical products in a globalized environment. However, national regulations can create significant barriers to pharmaceutical availability.

We must formulate our laws with a global focus. The globalization of regulation weakens national sovereignty but empowers transnational epistemic networks. For this reasons the pharmaceutical agencies are involved in several bilateral and multilateral cooperation activities with international partners. International cooperation is a key area of work for the agencies. This process will benefit of advancement in global governance and progress toward supranationalism.

The internationalization of the pharmaceutical industry, highly globalized, involves changes in policies, lifestyle and culture, and has altered drug research, production, and regulation. Editorial - The innovation and access to landscape. Regulatory harmonisation for better global health. Dec ICH contribute to the protection of public health froman international perspective.

Regulatory harmonisation offers many direct benefits as preventing duplication of clinical trials; streamlining the regulatory assessment process for new drug applications; and reducing the development times and resources for drug development. The Guidelines are developed through a process of scientific consensus with regulatory and industry experts.

Conference Paper. May Salón de Actos de la Facultad de Farmacia. Como de lo que se trata es de celebrar nuestro reencuentro, nada mejor que compartir nuestros recuerdos comunes, que es una forma de, en parte, de volver a vivirlos, y renovar nuestros lazos de amistad. Recordar es siempre algo selectivo. Nadie puede pretender ni la totalidad ni la objetividad.

Pero cada pequeño recuerdo, cada anécdota, conforma nuestra memoria colectiva. Al cabo de los años se pierden muchas vivencias. Tampoco podemos olvidar que nos aficionamos a escribir Memorias cuando realmente la estamos perdiendo, día a día, así que mil perdones, por los vacíos de estas notas. Michel de Montaigne decía que nuestra Memoria es un montón de espejos rotos.

Es una nueva vida que adquirimos y nos resulta valiosa. Por eso, creo que es bueno que estos días de reencuentro compartamos recuerdos. The Common Technical Document as academic guideline. Drug approval process involves different steps, including preclinical and clinical studies, and postmarketing research for ensure the quality, safety and efficacy of medicinal products. The objective of the ICH is to reach a common understanding of the technical requirements to support the registration process. These objectives are achieved through harmonised guidelines. The CTD arrange the information in a common format for use in reporting the technical requirements for a new product submission to regulatory authorities.

Pharmaceuticals in Latin America. The countries of Latin America should tend to strategies that favour trading or manufacturing of generic products, increasing competition and access to drugs. Governments require more and more capacity to assess the national and international legal frameworks applicable in intellectual property and to participate in negotiations processes in several forums and fields defending the rights of citizens without altering the property right. In this sense the region definitely has a pending account.

It is necessary that states contemplate the active policies to promote research and development in the pharmaceutical area. Latin American pharmaceutical overview. Jan Latin America is a diverse, multi-coloured and dynamic region; boast the highest life expectancy among developing regions. In Latin America persistent social exclusion and inequities in wealth distribution and in access and use of services are reflected in health outcomes. As a developing market, Latin America is quite complicated and diverse in terms of regulatory, reimbursement, market, demographic, and political characteristics.

The harmonization of pharmaceutical regulation has been initiated in conjunction with the creation of regional free trade zones. Five main free trade zones are developing: Regulatory frameworks overall have improved as a result of free trade and intellectual property agreements.

PREPARANDO EL ERASMUS

Regulatory enforcement bodies, quality investigators, proactive Good Clinical Practice GCP and policy development, have been cited as contributing to Latin America's explosive growth. Latin American countries are currently moving policies to support productive development and innovation. The local biotechnology industry is developing rapidly. Pharmaceutical innovation and non-patent protection. Europa,Pensamiento y Acción. El texto "Europa, Pensamiento y Acción. Su libro constituye una reflexión indispensable en un momento clave de la historia de la integración europea.

Son estos los gestos que sirven de inspiración y motivación para seguir trabajando por Europa". El libro es una crónica de la construcción europea centrada en las ideas fuerza que configuran los tratados,los sucesivos procesos de ampliación,y los posicionamientos personales de los principales líderes europeos. Incorporando el relato de cómo se ha vivido desde España este proceso bajo la perspectiva europeista. The pharmaceuticals industry in trouble. Health spending accounted for 9. The pharmaceutical sector is highly regulated. On describe the major characteristics of the world pharmaceutical industry as one increased globalization, changing structure of competition and increased competitiveness.

This are growing pressures on discovery and development. Drug liabilities become more frequent and more costly. The pharmaceutical industry is under immense pressure by external and internal stakeholders. Government and National Health Services are monopsonic practices.

Pharmaceutical companies are criticised for high prices, over-intensive sales and marketing activities, presents to medical doctors, clinical trials and industry-government alliances. Lawyers, medical journals, physicians, politicians, and the media use product liabilities and marketing activities to denounce pharmaceutical companies as culprits.

The pharmaceutical sector needs to demonstrate responsibility and take steps to increase awareness. Transparency would increase the credibility of the pharmaceutical industry. Corporate governance will prevent corruption by being in compliance with the legislation and establishing their own internal policies designed to prevent corruption. All firms will act more responsibly. In order to rebuild the trust the industry needs to work together and quickly. The originality and specificity of medicinal product.

Ethical challenges in the pharmaceutical industry. Drug liabilities become more frequent, more publicized, and more costly. Thorough review of the literature and newspapers indicates that the perception of ethical issues in the pharmaceutical industry is largely negative and highlights the scrutiny placed on pharmaceutical companies. The most prominent issues reported are drug safety, pricing, data disclosure, importation, clinical study design, marketing restrictions, DTC advertising, animal testing, internationalmarket, developing countries, issues related to vaccines, growth of drug counterfeiting, the cost effectiveness of treatments, and in the last ten years the Pharmaceutical fraud.

The codes for Corporate Social Responsibility need one profound revision. The pharmaceutical industry is, by nature, a sector where the ideas of corporate involvement, responsibility towards patients, ethical behaviour and an overall duty towards society are omnipresent. The ultimate ethical goal in the pharmaceutical industry is to discover and develop safe and efficacious drugs that allow patients to live longer, healthier and moreproductive lives,while making a profit to reward shareholders and to invest in research for the next generation of medicines.

Pharmaceutical industry urgently needs to eliminate internal misconduct in some executives and reaffirm before the society his real commitment, as always, for the innovation and the progress of the therapeutic in benefit of the humanity. Corporate responsibility and pharmaceutical fraud. The Health-Care fraudulent practices cost billions of dollars each year.

Breadcrumb

Fraud and corruption activities can take place in any healthcare systems, whether they are predominantly public or private, well funded or poorly funded, and in any area of healthcare delivery. Rooting out health care fraud is central to the well-being of both the citizens and the overall economy. Fraud and corruption in the healthcare sector are often hard to detect unlawful behaviour. Healthcare is increasingly becoming multinational and needs tackling as such. A major concern has been fraud schemes by pharmaceutical manufacturers and distributors.

The pharmaceutical industry's reputation has come under fire concerning the lack of transparency around its relationships with governments and the health community. The regulation of the prosecution of the pharmaceutical fraud it is too completely different in United Stated, EU and other countries.

It is very important for the sector react whit efficacy. Its it one challenge for the companies and for preserve the huge historical contribution in the health. Our society need to preserve this patrimony and increase his efficacy. Building trust and transparency are indispensable in the new policy on corporate social responsibility in the pharmaceutical industry. Challenges for the pharmaceuticals Policy in the EU. At the beginning of the 21st century, Europe was facing challenges such as pharmaceutical innovation, the increasing globalization of the sector and scientific breakthroughs.

A more competitive and innovative industry will generate more growth and sustainable jobs and also foster the development of new medicines for unmet medical needs. The EU has been losing ground in pharmaceutical innovation. To address these challenges, the Commission had tabled different proposals. In the Communication, in , about a Renewed Vision for the Pharmaceutical Sector lays down objectives relating to the future of the pharmaceutical sector. The objective was contributed to reinforcing the safety of pharmaceuticals, encouraging innovation, making medicines more accessible for European patients and affront challenges of globalisation.

The lost of credibility of the Institutions. The conclusions of The House of Commons Science and Technology Committee report examining the policy on homeopathy, it is a careful and thoughtful analysis. It is the best example of the responsibility of the Parliaments for protects the health right of the patients. His proposals will be valid for all the countries and will be global principle for regulation.

It is unacceptable for the National Health Authorities to license placebo products conferring upon them some of the status of medicines. Even if medical claims on labels are prohibited, the official licensing itself lends direct credibility to a product. Licensing paves the way for retail in pharmacies and consequently the patient's view of the credibility of homeopathy may be further enhanced.

The Governments runs the risk of endorsing homeopathy as an efficacious system of medicine. It is time to break this chain. Homeopathy should not be funded and the Agencies of Medicaments should stop licensing homeopathic products. Not changes the actual situation will lose the credibility of the Health Institutions. It is one more political inconsistency. Evaluation of Latin America Materia Medica and its influence on therapeutics. Mar International Academy of History of Pharmacy.

The essay is a summary of Prof. Valverde to the historiography of Latin America medicinal plants. One line of research was the information provided by the chroniclers,historians and naturalists of American drugs. The research focused on the presence of American drugs in the European Pharmacopoeias,the role played by the Royal Pharmacy of Madrid in the knowledge of American drugs and the difficulties of sending powerful drugs such as quinine to Spain.

New challenges for the information on medicines in the EU. Member States have adopted divergent rules and practices with regard to the provision of information, resulting in a situation of unequal access to information on medicinal products. In a system where the rules on key product information Summary of products characteristics and package leaflet are fully harmonised to ensure the same level of protection of public health across the Community, this objective is undermined if widely divergent national rules on the dissemination of such key information are allowed. Moreover, national rules and practices on information may lead to restrictions to the free movement of goods in violation of Article 28 of the Treaty, impacting negatively on the completion of a single market of pharmaceuticals which the harmonised legal framework on medicinal products tries to achieve.

The European Court of Justice has already found certain national provisions on information on medicinal products to be contrary to Article 28 of the Treaty1. In the European Union, the Summary of Products Characteristics SPC provides the most impartial and complete information about prescriptiononly medicines. The SPC represents the agreed position on a medicinal product as approved during the course of an official assessment process. As such, its content cannot be changed except with the approval of the originating competent authority.

The SPC is the basis of the information provided to health professionals on how to use the medicinal product safely and effectively. The SPC forms an intrinsic and integral part of the product's marketing authorisation. The SPC is, therefore, the most complete and objective information about a medicinal product that a patient can access. The underpinning principle of any proposals directed to improve the current status of the legal framework on information to patients is that European citizens have the right to access the information on prescriptiononly medicines that would benefit them.

Access to high quality medicines information approved and provided by the competent authorities is most desirable. The availability and the access to highquality medicines information that can be understood by the average European citizen, available in all languages, via the internet, should be one of the principal objectives to achieve in this area. This information should be provided by the official website of the relevant competent authority in each Member State and by the websites of the EU competent authorities in the case of centrally authorised medicinal products.

There is, therefore, no need to radically change the current legislation but there is a need to clarify the scope and implementation of the current provisions. The current rules governing the information, to be issued by the competent authorities, regarding authorised medicinal products, could be complemented with further rules facilitating the access to such documents for the "average" citizen. Stop losing ground in pharmaceutical innovation in the EU. Innovative medicines development in Europe.

Duties and professional responsibilities in the current pharmacy. Furthermore, the EU has been working with the U. In the keynote address examines the situation of Pharmacy Practice and the challenges of today's society. If international law is evolving drug overcoming the old national scientific and legal profession as a whole and through its various organizations, should be very favorable towards this current harmonization. We analyze the system of responsibilities and duties of the pharmacist and its impact on a good use of the drug in our society and, above all, promoting a positive environment to promote therapeutic innovation.

Jan El acceso al Medicamento. Regulation of nutritional and health claims made on food in the European Union. The development of foodstuffs and their components that provide a benefit beyond their traditional nutritional value has aroused considerable academic, commercial and legislative interest in recent decades.

We are speaking here, among other denominations applied, of functional, fortified and nutraceutical foods. In many cases there are still scientific challenges that have not been satisfactorily resolved, both in the identification of active elements, such as in the mechanisms of absorption, distribution and metabolism in the organism, in addition to uncertainties from the possible interaction of the various additives inter se and their possible physiological potentiations [9].

The situation can fairly be described as a scientific, health, economic and legal challenge. Los servicios farmacéuticos del Hospital de los Reyes,de Granada. Feb Universidad de Granada. Se trata de un estudio histórico completo de la Historia del Hospital de los Reyes, de Granada, basado en documentos originales manuscritos. Su fundación data de y el estudio analiza los documentos fundacionales y las sucesivas Constituciones de funcionamiento. Se incorpora el estudio de todos los Boticarios que sirvieron en el Hospital, desde su fundación.

El relato recoge la vida del Hospital en el contexto de la historia de la ciudad de Granada y las propiedades y recursos del Hospital. La colección de documentos inéditos y Reales Cédulas es importante, así como las informaciones sobre las medicaciones utilizadas. The regulation of paediatric medicines in the EU. The legal challenges in assisted human reproduction. Technological advances during the past decade have dramatically increased the success rates of ART.

Unlike the leaps that technology has taken, the law and public policy have been slower to advance. The legal regulation of the techniques that help to overcome infertility problems are based on the fundamental rights of the persons. The freedom to procreate, as a premise to the right to form a family, is the realisation of the free development of personality and, inserts itself in the scope of freedoms and not in that of rights, in a strict sense.

We need to consider the meaning of human procreation in all its aspects and entailments. The law must address transcendent ethical worries. However, there must not be confusion between the ethical and legal dimensions. The article identifies and defines, the main problems which face the legislator and which the legal system must respond to. The areas which need regulation are the foundational value of human, the protection of human dignity, the health of the human subjects, human freedom, the intrinsic value of new knowledge, the promotion of justice and equality, privacy, without forgetting, the relief of the suffering of those afflicted with infertility.

The regulation of informed consent is another essential element of the exercise of the assisted reproduction techniques. Legal systems must provide an adequate response to all of the above issues. Although there are some discrepancies between the legislation of different countries, there are also some significant similarities. The response in each country was conditioned by its cultural, religious and social traditions. Demographic crisis in Europe. With population numbers plummeting, Europe may be arguably committing slow demographic suicide.

The extremely lowfertility levels observed in some countries are the culmination of the process of social change that started with the demographic transition a few hundred years ago. There is growing concern about a decline in the total fertility rate worldwide, but nowhere is the concern greater than in OECD countries. Economics and evolutionary sciences have explored the interactions between mortality and fertility.

In the European Union life expectancy has risen considerably while the number of children per woman dropped significantly, since the s. Over the last thirty years, fertility rates in the region of current EU25 have dropped and sustained well below the replacement level of 2. The total fertility rate TFR was 1. European populations have already entered a period of negative population momentum and are expected to fall after Between and , the largest declines are expected to be observed in the new member States.

Policy makers must identify infertility as a priority within family, social-demographic and health policies, and become pro-active in developing appropriate policies.

Busca en el resumen del documento

Toward a global legal statute for medicinal products. Oct Key issues in pharmaceutical law. Proposals for work in the harmonization progressive of pharmaceutical law at international level. Con la infertilidad "Europa camina a un lento suicidio". Mar Foro de Reproducción Humana Asistida. The need of one international statute for medicinal products. The specifity of labile blood products and plasma derived products.

Labile blood products and plasma-derived products are very sensitive from a social viewpoint. It can carry diseases and therefore the risk factor necessitate constant vigilance. The donations are insufifficient. European as a whole fail to even cover 40 per cent of their needs in plasma for fractionation. The aspiration that all donations shall be voluntary,free and unpaid, is an altruistic objetive,which reality,unfortunately, contradicts every day.

The political dimensión of blood and plasma derivatives. The place of blood and plasma-derived products in the context of pharmaceuticals policy and law is a truly unique one. The biological origin and the many parameters described in this monography demonstrate the special nature of these life-saving medicines and the need for the recognition of their uniqueness in pharmaceutical laws and regulations. This in turn necessitates a pragmatic and unique approach to the way the therapies are paid for. The intrinsic differences between labile blood products and plasma-derived products must also be kept in mind.

A clear distinction needs to be made when discussing issues such as safety or self-sufficiency.

1. buscar checas valencia 30 euros.
2. maduras buscan chicos.
3. citas x internet coopesalud?
4. fiestas aviles 2018;

Whilst plasma-derived products have longer shelf lives and have gone through a very long and complex production process with numerous virus inactivation and removal steps at the different stages from collection to finished product, labile blood products are extracted from donated blood, either directly or in one or few manufacturing steps, and have much shorter shelf lives. The blood and plasma-derived product sector has therefore a complex political dimension.

The differences with the traditional pharmaceutical sector and the ethical aspects that unavoidably arise are at its roots. However the right of patients to healthcare from an ethical viewpoint should prevail over any other considerations. Sep Editorial Universidad de Granada. Rememora cuarenta años de actividad académica y algunas efemérides de la Historia de la Universidad y actividades desarrolladas por el Prof. Y la exposición recoge sumariamente las aportaciones del autor en estos cuarenta años al estudio de la dimensión jurídica del medicamento, con especial referencia al Estatuto jurídico del medicamento en la UE.

Tema al que el Prof. Los propios Tratados de la UE se refieren como objetivo de todas sus políticas el preservar la salud y los derechos de los consumidores. Esta complejidad aconsejó una Codificación que se produce en el año , pero no fue total.